BET bromodomain inhibitor (b)

CAS No. 1380087-89-7

BET bromodomain inhibitor (b)( CPI0610 | CPI 0610 | CPI-0610 )

Catalog No. M11568 CAS No. 1380087-89-7

CPI-0610 is a potent, selective, and cell-active BET bromodomain inhibitor CPI-0610 inhibits BRD4-BD1 with IC50 of 39 nM in time-resolved fluorescence energy transfer (TR-FRET ) binding assay.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 104 In Stock
5MG 187 In Stock
10MG 279 In Stock
25MG 556 In Stock
50MG 842 In Stock
100MG 1260 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    BET bromodomain inhibitor (b)
  • Note
    Research use only, not for human use.
  • Brief Description
    CPI-0610 is a potent, selective, and cell-active BET bromodomain inhibitor CPI-0610 inhibits BRD4-BD1 with IC50 of 39 nM in time-resolved fluorescence energy transfer (TR-FRET ) binding assay.
  • Description
    CPI-0610 is a potent, selective, and cell-active BET bromodomain inhibitor CPI-0610 inhibits BRD4-BD1 with IC50 of 39 nM in time-resolved fluorescence energy transfer (TR-FRET ) binding assay.
  • In Vitro
    Pelabresib (0-1500 nM; 72 hours; Multiple myeloma cell lines and primary MM cells) treatment reduces the viability of MM cells in a dose-dependent manner.Pelabresib (800 nM; 72 hours; INA6 and MM.1S cells) treatment leads to G1 cell cycle arrest.Pelabresib (800 nM; 72 hours; INA6 and MM.1S cells) treatment significantly increases apoptosis in MM cells after 72 hours. Cell Viability Assay Cell Line:Multiple myeloma (MM) cell lines and primary MM cells Concentration:0 nM, 200 nM, 400 nM, 600 nM , 800 nM, 1000 nM, 1200 nM, or 1500 nM Incubation Time:72 huors Result:Decreased viability of MM cells in a dose-dependent manner. Cell Cycle Analysis Cell Line:INA6 and MM.1S cells Concentration:800 nM Incubation Time:72 hours Result:Indeced G1 cell cycle arrest.Apoptosis AnalysisCell Line:INA6 and MM.1S cells Concentration:800 nM Incubation Time:72 hours Result:MM cells apoptosis was increased after 72 hours.
  • In Vivo
    Pelabresib (30-60 mg/kg; oral administration; for 28 days; MV-4-11 mouse xenograft model) treatment results in substantial suppression of tumor growth over the time period examined (41%, 80%, and 74% tumor growth inhibition, respectively), without any significant body weight loss in the animals. Animal Model:MV-4-11 mouse xenograft modelDosage:30 mg/kg once daily, 30 mg/kg twice daily, or 60 mg/kg once daily Administration:Oral administration; for 28 days Result:Suppressed of tumor growth, without any significant body weight loss in the animals.
  • Synonyms
    CPI0610 | CPI 0610 | CPI-0610
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    c-Myc
  • Recptor
    MYC| BRD4-BD1
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    1380087-89-7
  • Formula Weight
    365.81
  • Molecular Formula
    C20H16ClN3O2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 10 mM
  • SMILES
    O=C(N)C[C@@H]1N=C(C2=CC=C(Cl)C=C2)C3=CC=CC=C3C4=C1ON=C4C
  • Chemical Name
    (S)-2-(6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Xiao Y, et al. Rheumatology (Oxford). 2015 Aug 3
molnova catalog
related products
  • MYCi975

    MYCi975 is an orally active inhibitor of MYC.MYCi975 inhibits P493-6, MV411,SK-N-B2 cells viability in an MYC-dependent manner(IC50s of 3.7, 3.9, 6.4 μM, respectively).The initial lead, MYC inhibitor 361 (MYCi361), suppressed in vivo tumor growth in mice, increased tumor immune cell infiltration, upregulated PD-L1 on tumors, and sensitized tumors to anti-PD1 immunotherapy. However, 361 demonstrated a narrow therapeutic index.

  • EN4 MYC inhibitor

    EN4 MYC inhibitor is a covalent ligand that targets cysteine 171 (C171) of MYC.

  • 10058-F4

    10058-F4 is a specific c-Myc inhibitor that disrupts the association between the c-Myc and Max.